Icotrokinra vs Rusfertide
Overview
Icotrokinra is primarily a immune support peptide, while Rusfertide is used for weight management & metabolic.
This page compares Icotrokinra and Rusfertide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Rusfertide | |
|---|---|---|
| Category | Immune Support | Weight Management & Metabolic |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 19-108 mg |
| Frequency | — | once weekly, subcutaneous |
| Reported benefits | — | In the Phase 3 VERIFY trial, adding rusfertide to standard-of-care therapy allowed 76.9% of participants to achieve hematocrit control without phlebotomy during weeks 20-32, compared with 32.9% on placebo plus standard of care. Reported benefits are specific to polycythemia vera erythrocytosis management and have not been studied for other conditions. |
| Reported side effects | — | Injection-site reactions (56%) and anemia (16%) were the most common adverse events in clinical trials; labeled warnings include thrombocytosis and embryo-fetal toxicity. |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Rusfertide falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Rusfertide: FDA-approved.
Dosing. Typical dosing for Icotrokinra is not catalogued. Rusfertide is typically dosed at 19-108 mg (once weekly, subcutaneous).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Rusfertide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Rusfertide?
- Icotrokinra is primarily a immune support peptide, while Rusfertide is used for weight management & metabolic. Icotrokinra is FDA-approved for one or more indications, whereas Rusfertide is FDA-approved for one or more indications.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Rusfertide used for?
- A once-weekly injectable hepcidin-mimetic peptide FDA-approved to treat erythrocytosis in adults with polycythemia vera.
- Can you take Icotrokinra and Rusfertide together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Rusfertide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Rusfertide FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Rusfertide is FDA-approved for one or more indications.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Rusfertide — full monograph: mechanism, research, dosing & references